Skip to search formSkip to main contentSkip to account menu

teriflunomide 14 MG Oral Tablet [Aubagio]

Known as: Aubagio 14 MG Oral Tablet, teriflunomide 14 mg ORAL TABLET, FILM COATED [Aubagio] 
National Institutes of Health

Related topics

Related topics

14 relations
AubagioIndigo CarmineLactose MonohydrateMagnesium stearate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
2018
2018
Pharmacokinetic Bioequivalence Study of Two Formulations of Teriflunomide in Healthy Male Volunteers under Fasting Conditions
A generic formula containing 14 mg of teriflunomide (Terflimida® test formulation) in oral coated tablets was compared to the… 
2018
2018
Teriflunomide (Aubagio®) International Pregnancy Registry: Enrollment Update (P4.371)
Objective: The International Teriflunomide Pregnancy Exposure Registry will compare rates of birth defects (congenital… 
2016
2016
Effect of Teriflunomide (Aubagio®) on Gray Matter Pathology in Multiple Sclerosis (P3.062)
Objectives: The primary aim of this study was to define the effect of teriflunomide (Aubagio®) on the development of gray matter… 
2015
2015
The importance of reporting suspected adverse reactions caused by new drugs
Adverse drug reactions have been linked to hospitalization in 2.4% to 6.2% of cases involving hospital admissions.1,2 In 2011… 
2014
2014
▼Teriflunomide for multiple sclerosis
▼Teriflunomide (Aubagio—Genzyme Therapeutics), the main metabolite of the disease-modifying anti-rheumatic drug leflunomide,1 is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)